Rheumatologists are continually evolving treatment paradigms to get the best outcomes for their patients with rheumatoid arthritis, according to a review of biologic use between 1997 and 2015. The data from almost 3,000 adults in the Optimising Patient Outcomes in Australian Rheumatology (OPAL) database showed median persistence on individual biologics (bDMARDs) was for a relatively ...
Frequent biologic switching as clinicians chase best outcomes in RA: OPAL
By Mardi Chapman
10 Jul 2018